CL2016002402A1 - Composiciones inmunológicas que contiene histophilus somni atenuado - Google Patents

Composiciones inmunológicas que contiene histophilus somni atenuado

Info

Publication number
CL2016002402A1
CL2016002402A1 CL2016002402A CL2016002402A CL2016002402A1 CL 2016002402 A1 CL2016002402 A1 CL 2016002402A1 CL 2016002402 A CL2016002402 A CL 2016002402A CL 2016002402 A CL2016002402 A CL 2016002402A CL 2016002402 A1 CL2016002402 A1 CL 2016002402A1
Authority
CL
Chile
Prior art keywords
attenuated
histophilus somni
compositions containing
strain
immunological compositions
Prior art date
Application number
CL2016002402A
Other languages
English (en)
Inventor
Tammy Kolander
Paularaj Lawrence
Russell Bey
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of CL2016002402A1 publication Critical patent/CL2016002402A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cepa atenuada de histophilus somni que en su secuencia genómica carece de ciertos genes que codifican factores de virulencia y que la hacen incapaz de causar infección en bovinos; composición inmunológica que la comprende; uso para provocar inmunidad protectora contra una cepa virulenta; composición de vacuna; cepa de desafío altamente virulenta; y método para aumentar virulencia en histophilus somni.
CL2016002402A 2014-03-25 2016-09-23 Composiciones inmunológicas que contiene histophilus somni atenuado CL2016002402A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461970195P 2014-03-25 2014-03-25

Publications (1)

Publication Number Publication Date
CL2016002402A1 true CL2016002402A1 (es) 2017-05-26

Family

ID=52829377

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002402A CL2016002402A1 (es) 2014-03-25 2016-09-23 Composiciones inmunológicas que contiene histophilus somni atenuado

Country Status (19)

Country Link
US (2) US9592283B2 (es)
EP (2) EP3488862B1 (es)
JP (1) JP6405390B2 (es)
KR (1) KR101924271B1 (es)
CN (1) CN107197626B (es)
AU (1) AU2015236052B2 (es)
BR (1) BR112016021918A2 (es)
CA (1) CA2943786C (es)
CL (1) CL2016002402A1 (es)
DK (1) DK3488862T3 (es)
EA (1) EA038530B1 (es)
ES (1) ES2927971T3 (es)
HU (1) HUE059284T2 (es)
MX (1) MX2016012372A (es)
NZ (1) NZ724908A (es)
PH (1) PH12016501879A1 (es)
PL (1) PL3488862T3 (es)
TR (1) TR201907352T4 (es)
WO (1) WO2015148687A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6405390B2 (ja) * 2014-03-25 2018-10-17 メリアル インコーポレイテッド 弱毒ヒストフィルス・ソムニを含む免疫学的組成物
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
WO2019012141A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh IMPROVED POLYPEPTIDE MOLECULE WITH DOUBLE SPECIFICITY
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
RU2754005C1 (ru) * 2020-10-29 2021-08-25 Федеральное государственное бюджетное научное учреждение "Федеральный научный центр - Всероссийский научно-исследовательский институт экспериментальной ветеринарии имени К.И. Скрябина и Я.Р. Коваленко Российской академии наук" (ФГБНУ ФНЦ ВИЭВ РАН) Штамм бактерий histophilus somni, предназначенный для получения моно- и поливалентных иммуногенных композиций, направленных на специфическую профилактику гистофилеза (стадного бесплодия) рогатого скота
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
CN113174374B (zh) * 2021-05-19 2022-07-22 西南民族大学 一种牛病毒性腹泻病毒弱毒株及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
WO2000018429A2 (en) * 1998-09-25 2000-04-06 The Regents Of The University Of California Vaccine based on attenuated $i(haemophilus somnus)
US6770273B1 (en) * 1998-09-25 2004-08-03 Regents Of The University Of California Vaccine based on attenuated Haemophilus somnus
US20090068223A1 (en) * 2005-11-15 2009-03-12 Boehringer Ingelheim Vetmedica, Inc. Combination vaccine comprising an attenuated bovine viral diarrhea virus
US8586059B2 (en) * 2008-07-03 2013-11-19 Iowa State University Research Foundation, Inc. Cattle vaccines
US9597386B2 (en) * 2012-04-05 2017-03-21 Boehringer Ingelheim Vetmedica, Inc. Outer membrane proteins of Histophilus somni and methods thereof
WO2015066292A1 (en) * 2013-11-01 2015-05-07 Merial Limited Attenuated pasteurella multocidavaccines & methods of making & use thereof
JP6405390B2 (ja) * 2014-03-25 2018-10-17 メリアル インコーポレイテッド 弱毒ヒストフィルス・ソムニを含む免疫学的組成物

Also Published As

Publication number Publication date
WO2015148687A3 (en) 2015-12-23
JP2017517245A (ja) 2017-06-29
AU2015236052B2 (en) 2018-05-10
US10098941B2 (en) 2018-10-16
PL3488862T3 (pl) 2022-08-29
EP3488862B1 (en) 2022-05-04
TR201907352T4 (tr) 2019-06-21
WO2015148687A2 (en) 2015-10-01
PH12016501879B1 (en) 2017-01-09
CN107197626A (zh) 2017-09-22
US20150273045A1 (en) 2015-10-01
EP3122374A2 (en) 2017-02-01
CA2943786C (en) 2023-12-12
EA038530B1 (ru) 2021-09-10
NZ724908A (en) 2017-12-22
DK3488862T3 (da) 2022-08-01
US9592283B2 (en) 2017-03-14
CA2943786A1 (en) 2015-10-01
EP3488862A1 (en) 2019-05-29
US20170157232A1 (en) 2017-06-08
KR20160128427A (ko) 2016-11-07
JP6405390B2 (ja) 2018-10-17
EA201691915A1 (ru) 2017-04-28
HUE059284T2 (hu) 2022-11-28
KR101924271B1 (ko) 2019-02-22
ES2927971T3 (es) 2022-11-14
PH12016501879A1 (en) 2017-01-09
BR112016021918A2 (pt) 2017-10-24
AU2015236052A1 (en) 2016-11-10
MX2016012372A (es) 2017-05-30
EP3122374B1 (en) 2019-02-20
CN107197626B (zh) 2021-03-02

Similar Documents

Publication Publication Date Title
CL2016002402A1 (es) Composiciones inmunológicas que contiene histophilus somni atenuado
CO2019000099A2 (es) Composiciones que comprenden cepas bacterianas
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
BR112018011122A2 (pt) antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
CR20140069A (es) Formulaciones parenterales de vacunas contra los norovirus
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
PE20170243A1 (es) Composiciones de vacuna con adyuvante dual, preparacion y usos
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
NZ731659A (en) Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EA201790517A1 (ru) Способы и композиции для индуцирования защитного иммунитета против филовирусной инфекции
MX2017016401A (es) Composiciones inmunogenas.
MX2017008055A (es) Vacunacion.
ES2721755T3 (es) Vacunas contra el virus de la tilapia del lago
AU2016248452A8 (en) Bordetella pertussis immunogenic vaccine compositions
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
MX2017006744A (es) Composiciones adyuvantes y metodos relacionados.
GB2515222A (en) Use of flagellin as a vaccine
AR093424A1 (es) Vacunas atenuadas de mannheimia haemolytica y metodos para su elaboracion y uso